Skip to content

Effect of SGLT2 inhibitor on Renal Function and Urinary [TIMP-2] x [IGFBP7] in Patients Hospitalized for Acute Heart Failure; A Randomized Controlled Trail

Effect of SGLT2 inhibitor on Renal Function and Urinary [TIMP-2] x [IGFBP7] in Patients Hospitalized for Acute Heart Failure; A Randomized Controlled Trail

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20221003002
Enrollment
66
Registered
2022-10-03
Start date
2022-08-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute kidney injury and urinary [TIMP-2] x [IGFBP7] in patient hospitalized for acute heart failure Acute kidney injury, urinary [TIMP-2] x [IGFBP7], nephrocheck, acute heart failure, acute decompensated heart failure, SGLT2 inhibitor, renal function, biomarker

Interventions

SGLT2 inhibitor for add on therapy in acute heart failure patients for 28 days,Standard therapy in diuretic treatment in acute heart failure patients
SGLT2 inhibitor,Standard therapy

Sponsors

None listed

Eligibility

Sex/Gender
All
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. acute decompensated heart failure 1.1 dyspena at rest or dyspnea on minimal exertion 1.2 signs of pulmonary congestion 1.3 NT- proBNP more than 1600 pg/ml or more than 2000 pg/ml in atrial fibrillation patients 2. No vasodilator intravenous within 6 hours 3. No vasopressor and inotropic drug intravenous within 6 hours

Exclusion criteria

Exclusion criteria: 1. Type 1 diabetes 2. History of diabetic ketosis or ketosis 3. GFR (CKD-EPI) < 30 ml/min/1.73 square meter 4. History of prior SGLT2 inhibitor 5. Systolic blood pressure < 100 mmHg 6. Cardiogenic shock 7. History of percutaneous coronary intervention within 30 days before enrollment or planned for percutaneous coronary intervention 8. Immunosuppressive agent use 9. Acidemia with pH < 7.2 10. Sepsis or septic shock 11. Liver failure 12. Pregnancy or breast feeding

Design outcomes

Primary

MeasureTime frame
AKI 0,1,2,3,7,14,28 days after enrollment Creatinine,Change in [TIMP-2] x [IGFBP7] 0, 7, 28 days after enrollment Nephrocheck

Secondary

MeasureTime frame
Change in GFR 0,1,2,3,7,14,28 days after enrollment CKD-EPI,Length of stay 28 days after enrollment Researcher reports from medical data,Urine output 1, 2, 3 days after enrollment Measurement of urine output per day,Adverse event 28 days after enrollment Patients and researcher report adverse event ,28-day mortality 28 days after enrollment Resercher reports from medical record

Countries

Thailand

Contacts

Public ContactJananya Wattanakul

Bhumibol Adulyadej Hospital

koykoii.jw@gmail.com0853320562

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026